Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004009 · ClinicalTrials.gov registry record · Phase 1
R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia
A Phase 1 study of Leukemia, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Study locations
NCT00004009: Completed Phase 1 study of Leukemia, sponsored by University of Maryland, Baltimore.
NCT00004009 is a Phase 1 study of Leukemia that has completed, run by University of Maryland, Baltimore. The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004009, a Phase 1 study of Leukemia, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of R115777 in treating patients who have refractory or recurrent acute leukemia or chronic myelogenous leukemia.
Conditions Studied
Interventions
- DRUG tipifarnib
Study Locations (3)
Iowa
- University of Iowa College of Medicine - Iowa City
Maryland
- Marlene & Stewart Greenebaum Cancer Center, University of Maryland - Baltimore
New York
- University of Rochester Cancer Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-06 |
| Est. Completion | 2001-04 |
| Phase | Phase 1 |
What the finished NCT00004009 record still lists
NCT00004009 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which tipifarnib is the first listed.
NCT00004009 reports a single indexed study location in Iowa, Maryland, New York.
Frequently Asked Questions
What is clinical trial NCT00004009 about?
NCT00004009 is a clinical study titled "R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of R115777 in treating patients who have refractory or recurrent acute leukemia or chronic myelogenous leukemia.
What is the current status of trial NCT00004009?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-06. Estimated completion is 2001-04.
What conditions does trial NCT00004009 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00004009?
The interventions under investigation include: tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00004009?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004009 being conducted?
This trial has 3 study locations across Iowa, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
CIML NK Cells With Venetoclax for AML
RECRUITING · Phase 1
-
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
-
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
RECRUITING · Phase 1
-
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia